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JOCELYN DOWNIE and JENNIFER MARSHALL
Neuroimaging has provided insight into numerous neurological disorders in
children, such as epilepsy and cerebral palsy. Many clinicians and investi-
gators believe that neuroimaging holds great promise, especially in the areas
of behavioral and cognitive disorders. However, concerns about the risks of
various neuroimaging modalities and the potential for misinterpretation of
imaging results are mounting. Imaging evaluations also raise questions about
stigmatization, allocation of resources, and confidentiality. Children are partic-
ularly vulnerable in this milieu and require special attention with regards to
safety guidelines and modality adaptations. This article examines pediatric
neuroimaging practice through an ethics lens. Most authors in the field of
neuroethics focus on the future concerns of neuroimaging. In contrast, our
paper examines ethical matters surrounding current clinical applications in the
pediatric population. We first provide a brief overview of the neuroimaging
technologies most commonly used in a pediatric clinical context and then
discuss a variety of ethical issues arising from the use of these technologies.
Neuroimaging Technology Overview
Structural Neuroimaging
Presently, structural, anatomic neuroimaging is the most commonly employed
modality in the clinic.1 Through localizing anatomical abnormalities, structural
neuroimaging studies have demonstrated disorder-specific findings in children
with a wide range of developmental impairments prenatally and postnatally. In
clinical practice, structural neuroimaging is indicated in children with a wide
variety of congenital, metabolic, neoplastic, inflammatory, and traumatic con-
ditions. Computed tomography (CT) and magnetic resonance imaging (MRI)
are two of the major imaging modalities in this category. Blood, gray matter,
white matter, and spinal fluid are distinguished by differences in attenuation of
an X-ray beam (in CT) or by differences in their response to radiofrequency
pulses (in MRI).2
The strengths of CT are its low cost, examination speed, ready accessibility,
and easy use.3 New CT scanners produce high-resolution images in a matter of
minutes, allowing patients to undergo the procedure without the need for
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MRI is the most widely used imaging modality in clinical pediatrics.4 The
clinical community considers MRI safe because, after 20 years of use, the vast
majority of scans have been performed without incident and because no
radiation exposure is involved.5 MR imaging provides high anatomical resolu-
tion, and multiplanar imaging capability, which is not possible with CT scans.6
MRI is disadvantageous because imaging time is relatively long, the imaging
itself is motion sensitive, the scanner noise is loud, and the environment within
the apparatus is constrained.7 As discussed further in the section regarding
imaging risks, these circumstances may necessitate sedation in some children.
In addition, any plates, screws, or metallic implants are contraindications for
MRI use because they may give rise to tissue damage under the influence of the
magnetic field or malfunction in the case of electrical implants.8
Functional Neuroimaging
Functional imaging is broadly defined as those techniques used to provide
measures of brain activity.9 Functional neuroimaging modalities assume that
there is a link between increased local brain activity and/or increased regional
cerebral blood flow, blood volume, blood oxygen content, and changes in tissue
metabolite concentration.10 Functional modalities are being used to map local-
ized cognitive processing and to examine brain plasticity. Positron emission
tomography (PET), single photon emission computed tomography (SPECT),
and functional MRI (fMRI) are examples of functional neuroimaging technologies.
PET is based on the detection of photons arising from the decay of injected
radiotracer (i.e., radiolabeled molecules).11 With the ability to image various
radiotracers and their distribution within the brain, it is possible to follow
molecular interactions and pathways.12 Compared with CT and MRI, PET
scanning offers the advantage of assessment of physiological and pathophysi-
ological processes and can measure chemical changes that occur before visible
signs of disease are present on CT and MRI images.13 However, PET has several
disadvantages, such as exposure to radiation (the dosage is comparable to CT),
the substantial expense of the technology compared to other types of imaging,
limited availability, and the need for bladder catheterization and sedation in
some pediatric patients (though not routinely).14 SPECT is similar to PET but is
more readily available and considerably less expensive.15 This modality mea-
sures changes in blood flow and receptor activity using different radiotracers
while the data are used to create images of slices of brain on different planes.16
fMRI is a technique based on MRI that detects small fluctuations in the
magnetic signal resulting from changes in blood oxygen level associated with
brain activation.17 The most frequently used technique is known as “blood
oxygenation level dependent” (BOLD) contrast, which exploits tiny magneti-
zation differences between oxygenated and deoxygenated blood (brain activa-
tion is followed by an increase in the ratio of oxygenated to deoxygenated
blood).18 Thus, fMRI measures blood flow and is an indirect measure of brain
activity.19 Although fMRI is considered noninvasive and as safe as MRI with
the potential to provide insights into brain regions and networks associated
with behavioral, cognitive, and other neurological disorders, this modality has
several disadvantages in addition to those associated with MRI. For example,

































































































































different populations. Yet, aging, oxidative stress, and other factors may change
this relationship.20 Therefore, interpretation of images may be compromised.
Furthermore, image analysis techniques need to be improved for pediatric
populations21 as fMRI is very sensitive to motion (more so than conventional
MRI) and movement during scanning produces artifacts for which adjustments
need to be made.22 For example, although motion correction algorithms are
recommended, and often effective, they are not entirely satisfactory, and in
some circumstances may generate false signal assessments.23
Ethical Issues in the Pediatric Clinical Context
Risk Reduction and Description
In the pediatric clinical context, there are two very important risk-related
ethical imperatives —to reduce risk where possible and to describe risks as
accurately and completely as possible to those with the authority to provide
consent to neuroimaging (most commonly the parents). Some specific risks are
associated only with a specific neuroimaging modality, whereas unexpected
findings, lack of child-appropriate protocols and equipment, and potential
overuse of imaging technologies are problems common to all of the technolo-
gies. These risks have implications for clinical practice. In this section, we
explore some of the risks of each technology and then some of the risks
common to all of the technologies through the lens of risk reduction and/or risk
description. The risks discussed are those on which we believe the ethical
imperatives mentioned above would require action (Table 1).
MRI.
Direct physical risk: MRI scanners use a strong static magnetic field, a pulsed
gradient magnetic field, and a radiofrequency field to obtain images of the
body in selected planes.24 Another component of MRI is the strong static
magnetic field that is always present even when the scanner is not imaging.25
Due to the intrinsic properties of the MRI scanner and its environment, patients
are vulnerable to physical injury (see Table 1).
Detailed patient screening guidelines have been developed for the MR
environment (www.MRIsafety.com). These guidelines help to reduce the risk of
such harms as are encountered when a patient with a metal implant undergoes
an MRI. Unfortunately, these guidelines do not specifically address pediatric
concerns. Therefore, screening guidelines specific to children should be devel-
oped and disseminated.
According to Shellock and Crues,26 most of the reported cases of MR-related
injuries and the few fatalities that have occurred have been the result of failure to
follow safety guidelines or the use of outdated information regarding the safety
aspects of biomedical implants. For example, undetected or misplaced metal ob-
jects have caused injuries during MRI.27 Therefore, guidelines should be better
disseminated and compliance enforced. Furthermore, systemwide strategies to
decrease the incidence of serious errors should be adopted —for example, the use

































































































































Table 1. Risk Description
MRI CT PET/SPECT
Direct physical risk • Known and unknown risks
due to high-strength, pulsed,
and radiofrequency fields
• Risks due to metal objects in
MRI environment (“missile
effect”)
• Risks due to electronic or mag-
netic implantable devices
• Negative effects of X-ray
radiation
• Radiation hazard
Indirect physical risk • Risks due to side effects of
sedation
• Heating injury due to monitor-
ing equipment
• Risks due to side effects of
gadolinium-based contrast
agents
• Risks due to intravenous injection of
radiotracer
• Risks due to bladder catheterization
Direct psychological risk • Fear, distress and potentially
long-term psychological effects




• Ambiguous interpretation of clinical imaging results
• Risk of unexpected findings
• Potential risks due to lack of child-appropriate neuroimaging guidelines
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Further research into risks associated with MRI is also necessary. Only a few
epidemiological studies into MR exposure have been carried out; consequently,
there is an insufficient scientific basis for the assumption that MR exposure has
no long-term effects.29 More research will provide a more solid foundation for
claims about risks made during the consent process for MRI.
Indirect physical risk: The risks of MRI may not be directly related to the
properties of the MRI magnet and environment. For example, under certain
clinical circumstances, an MRI exam may require the administration of sedation
or a contrast agent. These procedures introduce risk due to potential serious
side effects.
The absence of patient motion is necessary for optimal MRI. Sedation has
frequently been used to eliminate motion in children. Indeed, historically,
sedation has been required in almost half of the pediatric patients who are
imaged.30 Unfortunately, pediatric sedation can have harmful effects. The risks
of sedation, depending on the drug used, commonly include drowsiness,
confusion, impaired judgment, nausea, and vomiting.31 Rarely, complications
may include difficulty breathing, brain damage, and death.32 Alternatives to
sedation in children are being, and should continue to be, explored: for
example, the use of video/audio programs, late night scanning, patient prep-
aration using simulation techniques, and increased speed of imaging time.33 In
addition, technological problems are associated with monitoring sedated pa-
tients in a MR imaging scanner. For example, electrocardiogram monitoring
during MR imaging has been associated with heating or burning injuries and
should be used with caution in this setting.34
Additional guidelines are also needed. Guidelines have been developed by
the American Academy of Pediatrics in its Monitoring and Management of
Pediatric Patients During and After Sedation for Diagnostic and Therapeutic Proce-
dures. However, disabled children may have unpredictable responses to seda-
tion.35 Therefore, clear sedation guidelines need to be developed for the
disabled pediatric population.
MRI delivery guidelines are also needed. For example, consider the use of
gandolinium in a pediatric population. Gandolinium is a commonly used MRI
contrast agent. It has a slower clearance in fetuses, neonates, and infants
compared to adults.36 Reported adverse effects include thrombophlebitis, hy-
potension, headache, nausea, and vomiting.37 Due to these possible adverse
events, clear guidelines should be developed around the use (or possible
elimination) of gandolinium and other contrast agents in MRI procedures in
children.
Direct psychological risk: The MRI procedure may produce considerable fear,
distress, and potentially long-term psychological effects for a significant pro-
portion of patients.38 Anxiety, fear, and stress due to claustrophobia in MRI
devices need to be taken into consideration in the clinic. Many children become
anxious during scanning and may become uncooperative.39 Familiarity and
comfort with the people acquiring the scan or bringing in a favorite blanket or
stuffed toy are some methods by which to make MRI more pleasant for the
child.40 The staff of the MRI center must be flexible and willing to make a

































































































































individual child.41 The findings from the studies just mentioned should be
considered by all facilities offering pediatric MRI, and standard operating
procedures based upon them should be developed and implemented.
CT. A significant risk associated with CT scanning is the negative effect of
X-ray radiation. This risk is generally considered quite small compared to the
benefits of accurate diagnosis and treatment. However, one report has suggested
that CT scans of children are often done without adjusting dose to weight, re-
sulting in up to 50% of the dose being unnecessary.42 Furthermore, children are
generally at a higher risk of long-term adverse health effects due to imaging
radiation exposure because of their greater life expectancy.43 The lowest radia-
tion dose necessary for an accurate diagnosis should be used.44 Significant dose
reductions, especially in children, can be achieved without compromising clini-
cal efficacy.45 Picano46 suggests that clinicians are not sufficiently aware of the
possible long-term health risks associated with radiological imaging. Clear guide-
lines need to be set for all levels of clinical applications of CT scanning.
PET/SPECT. The radiation hazard posed by PET is said to be low and
equivalent to the hazard posed by CT scan47 as the radioisotopes administered
do not stay in the body for long due to their short half-lives. However,
radiation dose level from intravenous injection of PET radiotracer in infants has
been reported in only one study.48 More research is therefore needed to
determine the actual risk of PET in children. This need for research is even
greater for SPECT as, compared to PET, SPECT uses lower energy isotopes that
have longer half-lives and as SPECT is frequently used in the clinic due to its
relative simplicity and lower costs.49
In addition, PET and SPECT imaging often require intravenous administration
of radiotracers. PET/SPECT technologists do not always have experience estab-
lishing intravenous access in children.50 This procedure may be particularly chal-
lenging and distressing for children, and, therefore, close attention should be
paid to the training of personnel to ensure that they have adequate skills in es-
tablishing pediatric intravenous access. Bladder catheterization should be per-
formed by experienced technologists with pediatric neuroimaging expertise.51
Risks common to various technologies. Both magnetic and radiological imaging
share additional risks that may be of particular concern in the pediatric
population. Special precautions need to be taken when reading the brain
images of children to ensure detection of any anomalies as well as appropriate
follow-up.52 In particular, concerns have arisen regarding functional imaging
for which findings are frequently equivocal in terms of clinical significance.53
Having an experienced radiologist, as opposed to a nonspecialist physician,
involved in the review of neuroimages or readily available for referral is
essential to the well-being of neuroimaging patients.
Reports of unexpected MRI findings in brain imaging are not uncommon in
the clinical domain and have been reported in pediatric populations.54 These
reports compel consideration of the ethical issues of disclosure of risk of
unexpected findings in the consent process as well as the appropriate responses
to unexpected findings (e.g., what parents should be told about the possibility

































































































































the evaluation of the findings, and who should be told of these findings).
Guidelines need to be created around the procedures to be followed to deal
with the prospect and realization of unexpected findings.55
There have been many complaints in the literature that child-appropriate
neuroimaging protocols have not been developed. These types of protocols
would ensure that pediatric subjects comprehend the procedure and experience
a minimum of fear.56 Such protocols would also ensure imaging environment
adaptations and modifications to improve data acquisition and accuracy in the
neuroimaging of children. For example, the reduction of scan time for children
ought to be prioritized, and video/audio presentation devices and technologies
that minimize motion difficulties ought to be readily available to the imaging
team.57 Even the technology needs to be improved, as, for example, allowing
easy placement of devices in newborn intensive care units and minimizing
imaging time will allow for safer and more accurate acquisition of information.58
Another risk common to neuroimaging technologies is the potential overuse.
Up to a third of all radiological examinations have been reported as totally or
partially inappropriate.59 Again, radiologists have an important role in protect-
ing children from unnecessary exposure to radiation and the risks associated
with neuroimaging by curtailing their overuse.60
Interpretation
Several articles have warned of the potential for misinterpretation or overinter-
pretation of imaging examination results.61 The reasons for this potential
misinterpretation are related to the technological infancy of most neuroimaging
modalities, the rapid evolution of the technology, lack of standardization, and
methodological inconsistencies.
The limits of interpretative powers. Conventional MRI and CT image interpre-
tation requires knowledge of normal brain anatomy and development, recog-
nition of findings in specific disorders, and an awareness of potential study
artifacts. Although neuroanatomical imaging measures the volume and shape
of brain structures, the underlying cause of any differences may not be deter-
minable.62 Regarding neurobehavioral disorders, most imaging studies of learn-
ing disabled patients using MRI or CT have not identified significant structural
pathology.63 Additionally, many neurological disorders are the result of com-
plex interactions between many factors, and causality may not be clearly
established.
Functional neuroimaging has encountered criticisms based on the interpre-
tation of functional–behavioral associations and the lack of standardization in
the field. For example, functional neuroimaging cannot determine that a par-
ticular cognitive process causes imaged brain activity because this association
has not been proven to be causal.64
Additionally, the structure and content of neuroimaging data sets currently
have no universally accepted standards.65 Data formats, statistical analyses,
behavioral descriptors, and choice of controls (or baseline conditions) are
poorly defined and variable across different laboratories. This makes accurate


































































































































The interpretation of neuroimaging examination results faces further chal-
lenges when children are imaged. Because the developing brain is constantly
changing, a certain degree of normal variability must be taken into consider-
ation when interpreting pediatric neuroimaging data.67 Brain structure varies
during childhood as do activation patterns in cognitive strategies measured in
functional imaging.68 Additionally, a number of neurological parameters in
children differ from those observable in adults and yet, for the pediatric
population, limited neuroimaging research data exist.69 For example, develop-
mentally accurate child brain maps are not yet freely available, resulting in the
use of adult brain maps for analysis that may lead to incorrect identification of
brain regions in children.70 For various ethical and practical reasons, extensive
neuroimaging studies with control groups (i.e., healthy children) have not been
carried out. However, many authors have called for improved and increased
research into pediatric neuroimaging in order to address questions surrounding
data analysis.71
Neuroimaging is still at a relatively early stage of development. Although it
has allowed researchers and clinicians to view the human brain more thor-
oughly than ever before, the comprehensive analysis, interpretation, and stan-
dardization of imaging data are daunting tasks.
The ethical implications. The present technological and interpretive limitations
directly influence the ethical aspects of neuroimaging in the clinic. Although
some structural changes (e.g., discrete tumors or lesions) can be unambigu-
ously identified via neuroimaging, other structural abnormalities can be much
more subtle.72 Neuroimaging is recommended by the American Academy of
Neurology (AAN) as part of the diagnostic evaluation of the child with cerebral
palsy and global developmental delay, to determine neurodevelopmental out-
come in encephalopathic term infants, and to evaluate the first nonfebrile
seizure in children. According to the AAN, whether MRI, CT, or other imaging
techniques are used depends on the disorder, the age of the patient, and
specific clinical circumstances. Comprehensive, as opposed to piecemeal, in-
struction regarding the clinical utility and accuracy of pediatric neuroimaging
is needed to aid in diagnosis and prognosis and to give clinical confidence.73
Functional imaging is very important for presurgical planning —especially in
epilepsy surgery —and has the potential to provide insight into neurological
and psychiatric disorders.74 However, in some cases, due to insufficient scien-
tific evidence, the use of functional imaging in the diagnosis of developmental
and behavioral disorders is not advocated. For example, the Practice Guideline
of the American Academy of Pediatrics in its Diagnosis and Evaluation of the
Child with ADHD does not recommend diagnostic neuroimaging in ADHD
patients. Moreover, the American Academy of Neurology does not advise the
use of functional modalities, such as SPECT, in the clinical diagnosis of autism.
Problems arise in the setting of standards because of the variability of reported
diagnostic accuracy, imaging techniques, timing of the imaging examination,
and variations in maturation of the developing brain.75 Given the plasticity of
pediatric neurodevelopment, the analysis of the images of children should
merit special attention at the level of the clinic. A healthy degree of humility
and realism supports admitting diagnostic and prognostic limitations while


































































































































A noticeable feature of some neuroimaging studies is the use of value-laden
language to describe various aspects of brain structure and function even
though normal brain anatomy and function has yet to be determined. The
language implies the existence of normal and abnormal brain templates and
increases the potential for the stigmatization of pathologically labeled individ-
uals. Special precautions will need to be taken in this regard in respect of
cognitive profiling, intelligence tests, and behavioral disorders diagnosis. De-
spite this, Giedd76 has noted “the growing use of SPECT scans to diagnose and
guide treatment for disorders such as ADHD and juvenile-onset bipolar disor-
der.” This trend is occurring notwithstanding discouragement from relevant
professional organizations such as the American Academy of Pediatrics and the
American Academy of Neurology77 regarding the use of neuroimaging to
diagnose behavioral disorders. The behavioral and cognitive categorization of
children using ambiguous labels, and the broad diagnostic criteria presently
available raise serious ethical concerns.
Research on children’s mental disorders has lagged behind parallel efforts for
adults.78 In addition, despite considerable progress in recent decades, the
validity of many forms of child and adolescent diagnostic modalities is far from
fully established.79 Although accurate diagnosis could reassure family members
and provide important information about prognosis, indiscriminate labeling,
especially in the area of behavioral or mental disorders, could be harmful.80 For
example, early childhood neuroimages may lead to the unnecessary labeling of
a child as developmentally delayed while not taking into consideration brain
plasticity and the potential resilience of children.81 Individuals could be seen as
hardwired for behavioral problems, chronically ill, and unable to change or
adapt. Using brain imaging to predict emotional and mental outcomes may
stigmatize a child and affect how he or she is raised. The image diagnosis may
influence clinical care as well as parental treatment and later educational
decisions.82 In addition, children diagnosed with behavioral and emotional
disorders are highly likely to receive peer rejection.83
Allocation of Resources
Serious ethical issues also arise when examining neuroimaging and allocation
of resources. At the societal level, pediatric neuroimaging raises several ques-
tions surrounding its potential exclusivity, expense, and the medicalization of
social phenomena. For example, with the advent of private MRI clinics, imag-
ing modalities may permit queue jumping so that any potential benefits will
favor those with the resources to afford access. Additionally, the expense of
neuroimaging may restrict access to wealthy communities and regions. This
potential inequality needs to be acknowledged, and investigations into the best
use of public funds for neuroimaging techniques should be undertaken. An-
other potential concern relates to the massive funds allowed for the develop-
ment of neuroimaging modalities to the detriment of basic community-based
and family services.84 Although technologically based interventions are impor-
tant for the study of brain development, the emphasis on neuroscience and


































































































































Neurobiological explanations may be viewed as more objective than environ-
mental descriptions. However, environmental factors, although more complex
and nuanced, may provide insight into the deeper social causes of particular
neurological disorders. A focus on neuroimaging procedures could channel
resources away from environmental concerns, such as the consequences of
poverty on children. For instance, not only is prematurity more common in
low-income populations, but the developmental outcomes for these infants
born into poverty are significantly worse than for middle-class preterm in-
fants.86 Elaborate technological answers to neurobehavioral problems are not
necessarily as immediately efficacious as basic public health responses.
Confidentiality
The importance of the privacy and confidentiality of children’s health informa-
tion has been recognized by several professional and international organiza-
tions.87 Neuroimaging information itself could be considered sensitive information.
For example, results from functional neuroimaging tests may be predictive in
nature or may be diagnostic for behavioral, cognitive, or mental disorders.
Furthermore, especially where results are equivocal, confidentiality must be
maintained so that findings with unclear functional interpretation are not
subject to misuse.88 Although considerable attention has been paid to establish-
ing practices directed at protecting patient privacy, still more work needs to be
done. For example, there will be increasing interest in the possibility of data
mining in banks of neuroimages. Thus, clinicians should consider anticipating
future research uses and including a consent to be contacted in the future about
research projects in the consent process for clinical neuroimaging.
Secondary information obtained in the process of patient screening also
raises ethical concerns. Specifically with regards to MRI procedures, patients
must be screened for such personal information as presence of IUDs, dia-
phragms, tattoos, and body piercings.89 Two questions immediately arise. First,
who should be given this secondary information? For example, can or should
the parents be told about body piercings that they know nothing about?
Second, how can inadvertent disclosure of this secondary information during
the screening process be avoided? For example, if a pregnancy test is included
in the screening process, how can the minor’s privacy be protected if the parent
has accompanied the minor to the screening?
Concern about confidentiality is one of the primary reasons young people
delay seeking healthcare services for sensitive issues.90 The protection of
privacy in adolescent care has been justified from a developmental perspective
based on adolescents’ need for increasing autonomy as they approach adult-
hood and their increasing capacity to give informed consent.91 The particular
problems that may be of concern to the pediatric populations undergoing
neuroimaging examinations mentioned above have not yet been thoroughly
addressed. Clinics must develop clear confidentiality policies and privacy-
protecting practices.92
Conclusion
Neuroimaging is a developing field that holds great promise in aiding diagno-

































































































































outlined in this paper, many unknowns and numerous complex risks surround
neuroimaging technologies. Children, especially disabled children, are particu-
larly vulnerable groups that require special attention. Clinicians within the
field of neuroimaging who work with the pediatric population ought to be
aware of the particular needs of children. Additionally, clear guidelines and
standards need to be developed around the use of neuroimaging technologies
to provide diagnostic and prognostic accuracy and confidence. The creation of
standards for a technology still in development could be a difficult task.
However, given the fact that these technologies are presently being used in the
clinic and perhaps imprudently, clinicians need guidance.
In our paper, we have highlighted the areas in need of further clarification
and research, including:
1. Development of detailed guidelines with respect to pediatric neuroimag-
ing, especially of disabled children.
2. Adaptation of neuroimaging modalities to accommodate the particulari-
ties of the pediatric population.
3. Clinician assurance that risks are accurately and completely disclosed to
parents and mature minors.
4. Development of guidelines for assessing risk versus benefit (e.g., when
pediatric neuroimaging is obligatory or optional).
5. Development of best practices for handling unanticipated findings.
6. Restraint in interpretation of results to mitigate inappropriate diagnoses
and prognoses.
7. Advancement of research into the environmental (including psychosocial
environment) influences on pediatric neurological disorders alongside the
development of neuroimaging technologies.
8. Development of clear confidentiality policies and privacy protection prac-
tices for the children undergoing neuroimaging examinations.
Through the resolution of these issues, neuroimaging could better achieve its
promise for the pediatric population. Safe and responsible use of neuroimaging
technologies and analysis of neuroimages promote the best interests and
well-being of the pediatric patient.
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